Critical Survey: Abliva AB (publ) (OTCMKTS:NEVPF) versus Syros Pharmaceuticals (NASDAQ:SYRS)

Abliva AB (publ) (OTCMKTS:NEVPF) and Syros Pharmaceuticals (NASDAQ:SYRS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Volatility & Risk

Abliva AB (publ) has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.

Earnings and Valuation

This table compares Abliva AB (publ) and Syros Pharmaceuticals’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abliva AB (publ)	$10,000.00	N/A	-$9.00 million	N/A	N/A
Syros Pharmaceuticals	$9.94 million	16.73	-$164.57 million	($5.01)	-1.24

Abliva AB (publ) has higher earnings, but lower revenue than Syros Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and target prices for Abliva AB (publ) and Syros Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abliva AB (publ)	0	0	0	0	N/A
Syros Pharmaceuticals	0	0	2	0	3.00

Syros Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 125.08%. Given Syros Pharmaceuticals’ higher probable upside, analysts clearly believe Syros Pharmaceuticals is more favorable than Abliva AB (publ).

Insider and Institutional Ownership

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Abliva AB (publ) and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abliva AB (publ)	N/A	-87.27%	-77.94%
Syros Pharmaceuticals	-1,656.34%	-395.36%	-88.41%

Summary

Syros Pharmaceuticals beats Abliva AB (publ) on 6 of the 10 factors compared between the two stocks.

About Abliva AB (publ)

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.